---
title: "Human Acellular Vessel Biologics License Application granted priority review by US FDA for the treatment of vascular trauma"
date: "2024-02-12T12:23:24.000Z"
publishedDate: "12 février 2024"
summary: "Humacyte has announced that the US Food and Drug Administration (FDA) has accepted and granted priority review to Humacyte’s Biologics License Application (BLA) seeking approval of the Human Acellular Vessel (HAV) in urgent arterial repair following extremity vascular trauma when synthetic graft is not indicated, and when autologous vein use is not feasible. The Prescription [&#8230;] The post Human Acellular Vessel Biologics License Application granted priority review by US FDA for the treatment of vascular trauma appeared first on Vascular News ."
importance: ""
sourceUrl: "https://vascularnews.com/human-acellular-vessel-biologics-license-application-granted-priority-review-by-us-fda-for-the-treatment-of-vascular-trauma/"
tags: ["France", "Actualité", "Vascular News — Latest"]
permalink: "/papers/2024-02-12-human-acellular-vessel-biologics-license-application-granted-priority-review-by-us-fda-for-the-treatment-of-vascular-trauma"
imageUrl: "https://vascularnews.com/wp-content/uploads/sites/7/2023/08/Humacyte-HAV.jpg"
imageCredit: "Image de l’article — droits possiblement réservés — https://vascularnews.com/human-acellular-vessel-biologics-license-application-granted-priority-review-by-us-fda-for-the-treatment-of-vascular-trauma/"
---

![Human Acellular Vessel Biologics License Application granted priority review by US FDA for the treatment of vascular trauma](https://vascularnews.com/wp-content/uploads/sites/7/2023/08/Humacyte-HAV.jpg)

*Crédit image : Image de l’article — droits possiblement réservés — https://vascularnews.com/human-acellular-vessel-biologics-license-application-granted-priority-review-by-us-fda-for-the-treatment-of-vascular-trauma/*

## L’essentiel

Humacyte has announced that the US Food and Drug Administration (FDA) has accepted and granted priority review to Humacyte’s Biologics License Application (BLA) seeking approval of the Human Acellular Vessel (HAV) in urgent arterial repair following extremity vascular trauma when synthetic graft is not indicated, and when autologous vein use is not feasible. The Prescription [&#8230;] The post Human Acellular Vessel Biologics License Application granted priority review by US FDA for the treatment of vascular trauma appeared first on Vascular News .

## Lien source

https://vascularnews.com/human-acellular-vessel-biologics-license-application-granted-priority-review-by-us-fda-for-the-treatment-of-vascular-trauma/
